ShiraTronics Initiates IDE Pivotal Study of Implantable Neuromodulation Therapy for Chronic Migraine

First Implants of Innovative Device Completed in the United States and Australia

ShiraTronics, a clinical-stage innovator in neuromodulation technology, today announced the initiation of its U.S. Food and Drug Administration (FDA) – approved Investigation Device Exemption (IDE) pivotal trial, the RELIEV-CM2 Clinical Study. The first implants of ShiraTronics neuromodulation therapy for Chronic Migraine have been completed in the United States and Australia, marking a new chapter in the company’s efforts to develop innovative solutions for individuals impacted by this disabling condition.